A study that was recently published in the “Irish Journal of Medical Science” has found that individuals who use mental health services in Ireland favorably view research on psychedelics. The study found that more than half of its participants were willing to try psychedelic therapy if their physicians recommended it.
However, the study also found evidence of therapeutic misalignment as the symptoms of some individuals who suffer from mental health disorders could be worsened by psychedelics.
For the study, the researchers conducted a survey that assessed the attitudes of individuals who suffered from mental health diseases towards psilocybin therapy and psychedelics in general. About 100 patients from St. Patrick’s University Hospital and Tallaght Community Mental Health Service took part in the survey.
The researchers found that most of the participants were in favor of research on psychedelic substances, with more than 70% agreeing that psilocybin ought to be tested for its medicinal value. Roughly 60% of patients admitted that they believed psilocybin qualified for a medical treatment status with another 54% stating that they would undergo psilocybin therapy if a physician recommended it. Another 30% stated that they believed psilocybin therapy could be useful for their own mental health condition.
Individuals who had used psychedelics prior to the study and younger people were also found to be more likely to be in favor of psychedelic therapy. Additionally, about 15% of the participants thought psychedelic therapy would be beneficial to people with mania or psychosis.
However, scientific evidence suggests otherwise. The author of the study, John R. Kelly, stated that psychedelics were interesting compounds that possessed the therapeutic potential to treat certain mental health conditions. He explained that psychedelics therapy wouldn’t be beneficial to everyone, as some disorders such as mania and psychosis could be exacerbated with the use of psychedelics.
Psychosis is a condition that impacts how an individual’s brain processes information. It can be triggered by extreme trauma, substance abuse or a mental disorder. On the other hand, mania is a condition that causes an individual to experience delusions, intense moods and euphoria.
Kelly notes that it would be interesting to carry out a larger study to find out whether the results would be reproduced, since this particular study was limited to a certain region and had a small sample size. Other researchers involved in the study include Veronica O’Keane, Gavin Rush, Kathryn Ledden, Yazeed Kelly, Rebecca Trant, Shannon Cleary, Roisin McManus, Conor McCandliss, Maeve Haran and Kate Corrigan.
The favorable attitude of patients towards potential psychedelic remedies is likely to encourage entities such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to ramp up their research efforts in order to find treatments suitable for those not being adequately helped by the existing medications.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
